FIELD: medicine. SUBSTANCE: the present innovation deals with combination of L-dofa and rilusol or any of its pharmaceutically acceptable salts and application of this combination for treating dyskinesia in case of Parkinson's disease. EFFECT: higher efficiency of therapy. 19 cl, 5 tbl
Authors
Dates
2004-03-10—Published
1999-04-22—Filed